mRNA Vaccines Market Size & Share 2026-2035

mRNA Vaccines Market Size

The mRNA vaccines market was valued at USD 6.2 billion in 2025. The market is expected to grow from USD 5.6 billion in 2026 to USD 7.2 billion in 2035, at a CAGR of 2.8% during the forecast period according to the latest report published by Global Market Insights Inc. The temporary decline reflects the post-pandemic market normalization, primarily driven by reduced demand for COVID-19 vaccines, lower government procurement volumes, declining uptake of booster doses, and the transition from emergency vaccination campaigns to routine immunization programs. Despite this short-term contraction, the market is expected to regain momentum over the forecast period, supported by the increasing adoption of mRNA-based vaccines, expanding applications beyond COVID-19, rising prevalence of infectious diseases, growing interest in regenerative medicine, and continuous advancements in mRNA delivery platforms and lipid nanoparticle (LNP) technologies.

mRNA vaccines are a class of vaccines that use messenger RNA (mRNA) to instruct cells to produce specific antigens that stimulate an immune response. By enabling the body to recognize and defend against infectious pathogens, these vaccines provide targeted immunity while offering significant advantages such as rapid development timelines, manufacturing flexibility, and scalability. These attributes have established mRNA technology as a transformative platform in modern vaccine development and have accelerated its application across a broad range of infectious and non-infectious diseases.

The market experienced exceptional growth during the COVID-19 pandemic, increasing from USD 56.2 billion in 2022 before declining sharply to USD 8.5 billion in 2024. This contraction was primarily attributed to the declining demand for COVID-19 vaccines, including Comirnaty and Spikevax, reduced large-scale government procurement, and lower booster vaccination rates across major markets. Additionally, the shift from pandemic-driven emergency vaccination programs to routine immunization schedules, coupled with saturation in vaccinated populations, significantly impacted overall market revenues. However, this decline represents a market correction following unprecedented pandemic-driven demand rather than a weakening of the underlying mRNA technology platform.

Despite the post-pandemic slowdown, infectious diseases such as COVID-19 and respiratory syncytial virus (RSV) continue to pose a significant global health burden, sustaining demand for next-generation vaccination strategies. Ongoing COVID-19 variant management through periodic booster programs and the increasing clinical focus on RSV prevention among pediatric and elderly populations are reinforcing the importance of mRNA-based vaccines. In addition, pharmaceutical companies are expanding mRNA research into influenza, cytomegalovirus (CMV), oncology, and other therapeutic applications, creating new opportunities for long-term market growth.

Furthermore, continuous innovation in mRNA design, delivery systems, and storage technologies is improving vaccine efficacy, stability, and accessibility. The development of next-generation vaccine candidates such as mNEXSPIKE and KOSTAIVE (ARCT-154) demonstrates ongoing progress toward enhanced thermostability, broader immune responses, and simplified distribution. These technological advancements are reducing logistical challenges, improving patient outcomes, and supporting wider adoption across hospitals, clinics, and government immunization programs. Consequently, continued product innovation and the diversification of mRNA applications beyond pandemic preparedness are expected to drive sustainable market growth throughout the forecast period.

The major players operating in the global mRNA vaccines market include Pfizer, BioNTech, Moderna, and Arcturus Therapeutics. These companies continue to strengthen their market position through sustained investment in research and development, robust clinical pipelines, strategic collaborations, global commercialization capabilities, and ongoing innovation aimed at expanding the application of mRNA technology across multiple disease indications.

mRNA Vaccines Market Trends

• Although the mRNA vaccines industry is experiencing a decline in revenue from its pandemic peak and is expected to remain under pressure through 2025 due to reduced COVID-19 vaccine demand, lower government procurement, and declining booster uptake, the market continues to benefit from the increasing need for rapid-response vaccine platforms, rising prevalence of chronic and infectious diseases, and sustained global investment in biotechnology. According to the World Health Organization (WHO), infectious diseases caused approximately 13.6 million deaths globally in 2023, accounting for 21% of all deaths worldwide. Growing emphasis on pandemic preparedness is encouraging governments and healthcare organizations to continue investing in mRNA technologies because of their rapid development timelines and platform flexibility.
• Despite the ongoing decline in commercial vaccine revenues, companies are increasingly shifting their focus toward high-value therapeutic applications to diversify revenue streams. Personalized oncology remains a key area of investment, with mRNA vaccines being tailored to patient-specific tumor profiles. Interest is also expanding in rare genetic diseases through protein replacement therapies.
• More than 235 mRNA-based drug candidates are currently in clinical development, while strategic collaborations between biotechnology companies, pharmaceutical manufacturers, and research organizations, together with AI-enabled mRNA sequence optimization, are accelerating research and commercialization beyond infectious disease vaccines.
• The current market slowdown is encouraging innovation in next-generation mRNA technologies that can improve product differentiation and long-term commercial potential. Self-amplifying mRNA (saRNA) and trans-amplifying mRNA platforms are gaining attention for their ability to achieve therapeutic efficacy with lower doses and prolonged protein expression.
• Similarly, circular mRNA is emerging as a promising technology due to its enhanced molecular stability and lower immunogenicity. Continuous advancements in lipid nanoparticle (LNP) delivery systems are further improving tissue-specific targeting, therapeutic efficacy, and safety profiles.
• As the industry transitions from pandemic-driven vaccine commercialization to broader therapeutic applications, regulatory authorities such as the U.S. FDA and the European Medicines Agency (EMA) are adapting regulatory pathways to accommodate the expanding mRNA pipeline. While mRNA vaccines continue to be regulated as biologics, ongoing discussions regarding the classification of certain mRNA therapeutics as gene therapies are expected to shape future regulatory and commercialization strategies.
• Continuous improvements in mRNA engineering, including modified nucleosides, optimized untranslated regions (UTRs), codon optimization, and advanced cap structures, are enhancing molecular stability, translation efficiency, and protein expression. At the same time, artificial intelligence is playing an increasingly important role in designing optimized mRNA sequences that minimize immunogenicity and improve therapeutic performance, supporting the next generation of mRNA-based medicines.
• The manufacturing landscape is also evolving in response to declining pandemic vaccine volumes. Production is gradually shifting from large-scale pandemic manufacturing facilities toward flexible, GMP-compliant, small-batch manufacturing capable of supporting personalized therapeutics and niche indications. Advances in base modification, purification technologies, and process optimization are improving manufacturing efficiency, product quality, and scalability.
• Contract development and manufacturing organizations (CDMOs) are investing in modular and automated manufacturing platforms to support both commercial-scale vaccine production and smaller, personalized therapeutic batches.
• In addition, initiatives such as the FDA's platform technology designation program have the potential to streamline future manufacturing approvals. As the market transitions beyond COVID-19, manufacturers are prioritizing flexible production capabilities, cost optimization, regulatory compliance, and scalable manufacturing infrastructure to support long-term growth.

mRNA Vaccines Market Analysis

Based on product, the global mRNA vaccines market is divided into Comirnaty, Spikevax, mRESVIA and other products. The Comirnaty segment dominated the market, accounting for approximately 70% of the revenue share in 2025. Although overall market revenues have declined following the normalization of COVID-19 vaccination demand, Comirnaty has maintained its leadership due to its established global presence, continued government procurement, and use in seasonal and booster immunization programs. The segment is projected to reach USD 4.9 billion by 2035, expanding at a CAGR of 2.6% during the forecast period.

• Comirnaty continues to benefit from its first-mover advantage, extensive regulatory approvals, and broad commercial availability across major global markets. The vaccine's proven efficacy, favorable safety profile, and continued recommendations for high-risk populations have supported its sustained utilization in seasonal booster campaigns.
• The long-standing collaboration between Pfizer and BioNTech, supported by robust global manufacturing and distribution capabilities, has enabled a reliable supply network, reinforcing the product's leading market position despite the overall market contraction.
• The Spikevax segment generated USD 1.4 billion in revenue in 2025 and is projected to expand at a CAGR of 3.1% from 2026 to 2035. While revenues have moderated following the decline in pandemic-related vaccination programs, the segment continues to benefit from its strong presence in developed markets, ongoing booster recommendations for high-risk populations, and continuous formulation updates targeting emerging SARS-CoV-2 variants. Moderna's advanced mRNA platform and strong clinical performance continue to position Spikevax as a key product within the evolving vaccine landscape.

Based on the application, the mRNA vaccines market is segmented into COVID-19 prevention and respiratory syncytial virus (RSV) prevention. The COVID-19 prevention segment dominated the market with a revenue share of 99.9% in 2025.

• The COVID-19 prevention segment maintained its leading position due to the widespread deployment of mRNA vaccines such as Comirnaty and Spikevax, supported by emergency use authorizations and large-scale government procurement during and after the pandemic.
• Continued demand for booster doses and updated vaccines targeting newly emerging variants has helped sustain revenue generation, although overall vaccination volumes have declined from pandemic peak levels.
• Furthermore, strong government immunization initiatives and public health programs have supported high vaccination coverage, reinforcing the segment's market leadership.
• The respiratory syncytial virus (RSV) prevention segment is anticipated to grow at a CAGR of 8.4% during the forecast period, driven by the expansion of mRNA technology beyond COVID-19 and increasing awareness of RSV. The rising incidence of RSV infections, particularly among pediatric and geriatric populations, is accelerating demand for effective mRNA-based preventive vaccines.

Based on patient, the mRNA vaccines market is classified into pediatric, adult and geriatric. The pediatric segment accounted for USD 2 billion and is expected to grow at a CAGR of 2.5% during the forecast period.

• The pediatric population remains a primary focus of national immunization programs, with governments prioritizing childhood vaccination to reduce the spread of infectious diseases.
• The high susceptibility of infants and young children to respiratory infections, particularly RSV, continues to drive demand for mRNA-based vaccines.
• Furthermore, expanding pediatric clinical trials and increasing regulatory approvals for mRNA vaccines are expected to strengthen the segment's long-term growth potential.
• The adult segment accounted for a significant share of market revenue in 2025 and is projected to grow at a CAGR of 3.1% during the forecast period. Although adult vaccination demand has declined following the pandemic, continued booster recommendations for high-risk populations and increased exposure to infectious diseases are expected to support steady market growth.
• The geriatric segment also represented a significant share of the market in 2025 and is anticipated to expand at a CAGR of 2.7% during the forecast period. The growing elderly population remains highly vulnerable to severe complications associated with infectious diseases such as COVID-19 and RSV, supporting the continued demand for preventive mRNA vaccines.

Based on end use, mRNA vaccines market is classified into hospitals and clinics, government immunization programmes, and other end users. The government immunization programmes segment dominated the market with a revenue share of 63.2% in 2025 and is expected to reach USD 4.2 billion within the forecast period.   

• Government organizations play a vital role in funding, procuring, and distributing mRNA vaccines such as Comirnaty and Spikevax on a large scale.
• National immunization programs continue to support broad vaccination coverage, particularly for high-risk populations and seasonal booster campaigns, sustaining vaccine demand despite the post-pandemic market decline.
• In addition, global partnerships and public health initiatives have strengthened vaccine supply chains and improved accessibility, further supporting the segment's leading position.
• The hospitals and clinics segment accounted for a significant share of market revenue in 2025 and is projected to grow at a CAGR of 4.4% during the forecast period. These facilities remain the primary sites for administering mRNA-based vaccines and emerging therapeutic products, supported by advanced cold-chain infrastructure, trained healthcare professionals, and comprehensive patient monitoring capabilities.

North America mRNA Vaccines Market

The North America market dominated the global market with a market share of 45.3% in 2025.

• The U.S. market was valued at USD 23.9 billion in 2022 and USD 7.7 billion in 2023. The market further declined from USD 3.6 billion in 2024 to USD 2.6 billion in 2025, reflecting the continued normalization of COVID-19 vaccination programs and reduced booster uptake.
• North America remains home to leading mRNA innovators such as Moderna, Pfizer, and BioNTech (through U.S. partnerships). Despite the decline in COVID-19 vaccine revenues, these companies continue to strengthen the regional market through advanced R&D capabilities, robust clinical trials, and well-established manufacturing infrastructure, supporting the development of next-generation mRNA vaccines and therapeutics.
• The region's well-developed healthcare infrastructure, including hospitals, clinics, and research institutions, continues to facilitate the adoption and distribution of mRNA-based therapies. These facilities support cold-chain logistics, clinical research, and personalized medicine, enabling the administration of both preventive vaccines and emerging therapeutic applications.
• The increasing burden of chronic diseases, infectious diseases, and cancer, coupled with a growing aging population, is creating long-term opportunities for mRNA-based therapeutics. As COVID-19 vaccine revenues decline, manufacturers are increasingly focusing on oncology, rare genetic disorders, and other therapeutic indications to drive future market growth.

Europe mRNA Vaccines Market

Europe market accounted for USD 2 billion in 2025 and is anticipated to show lucrative growth over the forecast period.

• Governments and private investors across Europe continue to increase funding for biotechnology and mRNA research. Countries including Germany, France, and the UK are investing in manufacturing infrastructure, talent development, and academic-industry collaborations, strengthening Europe's position as a key hub for mRNA innovation and production.
• Europe benefits from a well-established research ecosystem comprising leading universities, biotechnology clusters, and extensive clinical trial networks. These collaborative environments continue to accelerate innovation in mRNA design, delivery technologies, and therapeutic applications beyond COVID-19 vaccines.

Asia Pacific mRNA Vaccines Market

The Asia Pacific market is anticipated to grow at the highest CAGR of 3.5% during the analysis timeframe.

• Countries including China, India, Japan, and South Korea are making substantial investments in biotechnology infrastructure, mRNA research, and manufacturing facilities. Supported by government initiatives, public-private partnerships, and foreign investments, the region is emerging as a major hub for contract development and manufacturing organizations (CDMOs), strengthening global mRNA production capabilities.
• Governments across Asia Pacific are actively supporting mRNA research and development through national biotechnology programs, funding initiatives, and policy support aimed at enhancing pandemic preparedness and accelerating vaccine and therapeutic development. These initiatives are expected to support long-term market growth beyond the current decline in COVID-19 vaccine demand. 

Latin American mRNA Vaccines Market

The Latin America market is experiencing robust growth over the analysis timeframe.

• The region continues to face a high burden of infectious diseases, including dengue, Zika, and influenza. The rapid development capabilities of mRNA platforms make them well suited for addressing emerging public health challenges, supporting continued investment despite the slowdown in COVID-19 vaccine demand.
• Brazil is witnessing growing interest in expanding mRNA technology beyond infectious diseases into oncology and rare genetic disorders. Personalized cancer vaccines and protein replacement therapies are gaining momentum through ongoing clinical research and international collaborations, creating new long-term growth opportunities for the regional market.

Middle East and Africa mRNA Vaccines Market

The Middle East & Africa (MEA) market is experiencing robust growth over the analysis timeframe.

• Saudi Arabia's Vision 2030 initiative continues to be a major driver of regional market development. The government is investing significantly in healthcare modernization, biotechnology infrastructure, and local manufacturing capabilities to strengthen domestic vaccine production, foster innovation, and reduce dependence on imported biopharmaceutical products.
• The region is expanding state-of-the-art research centers and biomanufacturing facilities to support the complete development cycle of RNA-based therapeutics, from gene sequencing to commercial-scale manufacturing. These investments are expected to strengthen regional capabilities and position the Middle East as an emerging hub for RNA-based medicines.

mRNA Vaccines Market Share

The mRNA vaccines industry is characterized by a dynamic and moderately consolidated competitive landscape, led by a combination of established pharmaceutical companies and emerging biotechnology firms. Despite the overall decline in market revenues following the COVID-19 pandemic, leading players such as Moderna, BioNTech, and Pfizer continue to account for 100% of the global market. Their strong market position is supported by extensive investments in research and development, robust manufacturing capabilities, global commercialization networks, regulatory expertise, and expanding pipelines targeting infectious diseases, cancer, and rare genetic disorders.

To maintain their competitive advantage amid declining COVID-19 vaccine demand, these companies are increasingly focusing on portfolio diversification through strategic collaborations, mergers and acquisitions, licensing agreements, and continued investment in next-generation mRNA technologies. They are also adopting value-based pricing strategies and expanding into new therapeutic indications to improve patient access and address evolving clinical needs across global markets.

At the same time, emerging biotechnology companies are driving innovation through the development of advanced delivery technologies, including self-amplifying mRNA (saRNA), oral and inhaled mRNA formulations, and artificial intelligence-enabled mRNA design platforms. Their growing presence is particularly evident in Asia Pacific, Latin America, and the Middle East, where expanding biotechnology investments, improving healthcare infrastructure, and increasing awareness of mRNA technologies are creating new market opportunities.

As the market transitions from pandemic-driven vaccine demand toward broader therapeutic applications, companies are continuously expanding their product portfolios to include next-generation vaccines and personalized mRNA therapeutics. This strategic shift is expected to strengthen long-term competitiveness, accelerate innovation, and support the future growth of the global market despite the current period of market normalization.

mRNA Vaccines Market Companies

Prominent players operating in the mRNA vaccines industry are as mentioned below:

• Global players
  • Pfizer
  • BioNTech
  • Moderna
• Pipeline players
  • Daiichi Sankyo
  • Ethris
  • Meiji Seika Pharma
  • Arcturus Therapeutics
  • Sanofi
  • Providence Therapeutics
  • Strand Therapeutics
  • Orna Therapeutics

• Moderna

Moderna leads the mRNA vaccines market with a share of ~70% in 2025. Moderna’s competitive edge lies in its extensive mRNA platform, rapid development capabilities, and robust manufacturing infrastructure, allowing it to scale quickly and diversify across multiple therapeutic areas.

• BioNtech

BioNTech leverages deep expertise in immuno-oncology and AI-driven mRNA design, offering highly personalized cancer therapies and maintaining a strong pipeline across infectious diseases and rare conditions.

• Pfizer

Pfizer benefits from global reach, regulatory strength, and its strategic partnership with BioNTech, enabling swift mRNA vaccine deployment and expansion into broader therapeutic applications.

mRNA Vaccines Industry News

• In August 2025, Pfizer Inc. and BioNTech announced the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the companies LP.8.1-adapted monovalent COVID-19 vaccine for use in adults ages 65 years and older, as well as in individuals ages 5 through 64 years with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.
• In September 2024, Primrose Bio, a leading biotechnology company specializing in technologies that improve the manufacturing of next-generation therapeutics, and ExPLoRNA Therapeutics, a pioneering biotechnology company advancing mRNA technologies, vaccines, and therapeutics, announced a strategic partnership aimed at jointly developing and marketing products for mRNA medicines.
• In July 2024, GSK plc and CureVac N.V. announced they have restructured their existing collaboration into a new licensing agreement, allowing each company to prioritize investment and focus their respective mRNA development activities. 
• In December 2022, Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) vaccines, and Merck, known as MSD, outside of the U.S. and Canada, announced that the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA.

The mRNA vaccines market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue (USD Million) from 2022 – 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Comirnaty
• Spikevax
• mRESVIA
• Other products          

Market, By Application

• COVID-19 prevention
• Respiratory syncytial virus (RSV) prevention

Market, By Patient

• Pediatric
• Adult
• Geriatric

Market, By End Use

• Hospitals and clinics
• Government immunization programmes
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea

• Latin America
  • Brazil
  • Mexico
  • Argentina

• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE